Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1990 1
1991 2
1992 2
1993 31
1994 73
1995 101
1996 111
1997 157
1998 183
1999 226
2000 269
2001 282
2002 301
2003 301
2004 313
2005 329
2006 400
2007 397
2008 414
2009 464
2010 506
2011 533
2012 579
2013 546
2014 634
2015 603
2016 655
2017 616
2018 560
2019 639
2020 660
2021 641
2022 648
2023 603
2024 204

Text availability

Article attribute

Article type

Publication date

Search Results

11,662 results

Results by year

Filters applied: . Clear all
Page 1
The Role of MDM2 Amplification and Overexpression in Tumorigenesis.
Oliner JD, Saiki AY, Caenepeel S. Oliner JD, et al. Cold Spring Harb Perspect Med. 2016 Jun 1;6(6):a026336. doi: 10.1101/cshperspect.a026336. Cold Spring Harb Perspect Med. 2016. PMID: 27194168 Free PMC article. Review.
Genetic amplification and inheritance of MDM2 promoter single-nucleotide polymorphisms (SNPs) are the two best-studied mechanisms for up-regulating MDM2 activity. This article provides an overview of these events in human cancer, highlighting the frequent occurrence …
Genetic amplification and inheritance of MDM2 promoter single-nucleotide polymorphisms (SNPs) are the two best-studied mechanisms for …
Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell Death.
Koo N, Sharma AK, Narayan S. Koo N, et al. Int J Mol Sci. 2022 Apr 30;23(9):5005. doi: 10.3390/ijms23095005. Int J Mol Sci. 2022. PMID: 35563397 Free PMC article. Review.
Named as the guardian of the genome, p53 is a tumor suppressor that regulates cell function, often through many different mechanisms such as DNA repair, apoptosis, cell cycle arrest, senescence, metabolism, and autophagy. One of the genes that p53 activates is MDM2, which …
Named as the guardian of the genome, p53 is a tumor suppressor that regulates cell function, often through many different mechanisms such as …
MDM2- an indispensable player in tumorigenesis.
Zafar A, Khan MJ, Naeem A. Zafar A, et al. Mol Biol Rep. 2023 Aug;50(8):6871-6883. doi: 10.1007/s11033-023-08512-3. Epub 2023 Jun 14. Mol Biol Rep. 2023. PMID: 37314603 Free PMC article. Review.
Murine double minute 2 (MDM2) is a well-recognized molecule for its oncogenic potential. ...Alterations in the expression levels of MDM2 occur in multiple types of cancers resulting in uncontrolled proliferation. ...
Murine double minute 2 (MDM2) is a well-recognized molecule for its oncogenic potential. ...Alterations in the expression levels of …
Mdm2 promotes the rapid degradation of p53.
Haupt Y, Maya R, Kazaz A, Oren M. Haupt Y, et al. Nature. 1997 May 15;387(6630):296-9. doi: 10.1038/387296a0. Nature. 1997. PMID: 9153395
This effect of Mdm2 requires binding of p53; moreover, a small domain of p53, encompassing the Mdm2-binding site, confers Mdm2-dependent detstabilization upon heterologous proteins. Raised amounts of Mdm2 strongly repress mutant p53 accumulation in tum …
This effect of Mdm2 requires binding of p53; moreover, a small domain of p53, encompassing the Mdm2-binding site, confers M …
The role of the MDM2/p53 axis in anti-tumor immune responses.
Brummer T, Zeiser R. Brummer T, et al. Blood. 2023 Jul 19:blood.2023020731. doi: 10.1182/blood.2023020731. Online ahead of print. Blood. 2023. PMID: 37467495 Free article.
The direct effects of MDM2-inhibition or MDM2 deletion in effector T cells are discussed in the context of cancer immunotherapy. The preclinical findings are connected to clinical studies using MDM2-inhibition to enhance anti-tumor immunity in patients. In ag …
The direct effects of MDM2-inhibition or MDM2 deletion in effector T cells are discussed in the context of cancer immunotherap …
Small-molecule MDM2 inhibitors in clinical trials for cancer therapy.
Wang S, Chen FE. Wang S, et al. Eur J Med Chem. 2022 Jun 5;236:114334. doi: 10.1016/j.ejmech.2022.114334. Epub 2022 Apr 8. Eur J Med Chem. 2022. PMID: 35429910 Review.
Herein, we will review the function of MDM2 and provide a comprehensive and updated overview of small-molecule MDM2 inhibitors in different clinical phases for cancer therapy, especially focusing on the identification and optimization, and preclinical/clinical studi …
Herein, we will review the function of MDM2 and provide a comprehensive and updated overview of small-molecule MDM2 inhibitors …
MDM2 Implications for Potential Molecular Pathogenic Therapies of Soft-Tissue Tumors.
Sun SY, Crago A. Sun SY, et al. J Clin Med. 2023 May 24;12(11):3638. doi: 10.3390/jcm12113638. J Clin Med. 2023. PMID: 37297833 Free PMC article. Review.
Murine double minute 2 (MDM2, gene name MDM2) is an oncogene that mainly codes for a protein that acts as an E3 ubiquitin ligase, which targets the tumor suppressor protein p53 for degradation. ...The application of cellular stress leads to changes in the binding of …
Murine double minute 2 (MDM2, gene name MDM2) is an oncogene that mainly codes for a protein that acts as an E3 ubiquitin liga …
Mdm2 as a chromatin modifier.
Wienken M, Moll UM, Dobbelstein M. Wienken M, et al. J Mol Cell Biol. 2017 Feb 1;9(1):74-80. doi: 10.1093/jmcb/mjw046. J Mol Cell Biol. 2017. PMID: 27927750 Free PMC article. Review.
Mdm2 also cooperates in gene repression with the PRC1 protein RING1B, a H2AK119 ubiquitin ligase. ...So far, the majority of clinically tested Mdm2 inhibitors target its binding to p53 but do not affect the new functions of Mdm2 described here. ...
Mdm2 also cooperates in gene repression with the PRC1 protein RING1B, a H2AK119 ubiquitin ligase. ...So far, the majority of clinical …
Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens.
Alaseem AM. Alaseem AM. Saudi Pharm J. 2023 Oct;31(10):101790. doi: 10.1016/j.jsps.2023.101790. Epub 2023 Sep 16. Saudi Pharm J. 2023. PMID: 37818252 Free PMC article. Review.
It provides a rationale for combining MDM2 inhibitors with other therapeutic approaches in the management of cancer, taking into consideration ongoing clinical trials that evaluate the combination of MDM2 inhibitors. The review explores the current status of MDM2 …
It provides a rationale for combining MDM2 inhibitors with other therapeutic approaches in the management of cancer, taking into cons …
MDM2, an introduction.
Iwakuma T, Lozano G. Iwakuma T, et al. Mol Cancer Res. 2003 Dec;1(14):993-1000. Mol Cancer Res. 2003. PMID: 14707282 Review.
MDM2 functions as an E3 ubiquitin ligase to degrade p53. MDM2 also binds another tumor suppressor, ARF. This interaction sequesters MDM2 in the nucleolus away from p53, thus activating p53. Many additional MDM2 interacting proteins have been identified …
MDM2 functions as an E3 ubiquitin ligase to degrade p53. MDM2 also binds another tumor suppressor, ARF. This interaction seque …
11,662 results
You have reached the last available page of results. Please see the User Guide for more information.